Loading...
XNASLFCR
Market cap268mUSD
Dec 27, Last price  
7.28USD
1D
-2.80%
1Q
47.07%
Jan 2017
-47.25%
Name

Lifecore Biomedical Inc

Chart & Performance

D1W1MN
XNAS:LFCR chart
P/E
22.32
P/S
2.09
EPS
0.33
Div Yield, %
0.00%
Shrs. gr., 5y
5.08%
Rev. gr., 5y
-25.46%
Revenues
128m
+24.20%
205,230,000231,953,000210,498,000238,527,000235,938,000238,224,000276,729,000317,552,000441,708,000476,813,000539,257,000541,099,000532,257,000524,227,000557,559,000590,366,000544,161,000185,786,000103,269,000128,261,000
Net income
12m
P
5,402,0008,651,00029,189,00013,542,0007,730,0003,984,0003,920,00012,696,00022,587,00019,145,00013,544,000-11,641,00010,590,00024,829,0002,122,000-38,191,000-32,665,000-46,084,000-102,190,00012,013,000
CFO
-217k
L-99.37%
13,048,00010,865,000-2,062,00017,520,0009,435,0007,483,00014,469,00022,181,00021,230,00021,045,00026,155,00021,784,00029,327,00019,779,00016,020,000-17,041,00015,017,000-24,399,000-34,458,000-217,000
Earnings
Aug 08, 2025

Profile

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
IPO date
Feb 15, 1996
Employees
689
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
128,261
24.20%
103,269
-44.42%
185,786
-65.86%
Cost of revenue
94,986
127,235
185,705
Unusual Expense (Income)
NOPBT
33,275
(23,966)
81
NOPBT Margin
25.94%
0.04%
Operating Taxes
183
301
(5,839)
Tax Rate
0.55%
NOPAT
33,092
(24,267)
5,920
Net income
12,013
-111.76%
(102,190)
121.75%
(46,084)
41.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
572
4,822
(789)
BB yield
-0.28%
-2.03%
0.27%
Debt
Debt current
4,906
1,850
45,625
Long-term debt
134,531
121,753
122,475
Deferred revenue
4,703
103,745
Other long-term liabilities
30,486
104,392
190
Net debt
130,975
116,562
177,045
Cash flow
Cash from operating activities
(217)
(34,458)
(24,399)
CAPEX
(17,921)
(20,763)
(28,134)
Cash from investing activities
(17,921)
(4,153)
81,768
Cash from financing activities
7,509
39,700
(57,021)
FCF
15,873
30,881
56,759
Balance
Cash
8,462
19,091
1,643
Long term investments
(12,050)
(10,588)
Excess cash
2,049
1,878
Stockholders' equity
(123,906)
(176,191)
(59,215)
Invested Capital
343,357
389,474
320,633
ROIC
9.03%
1.62%
ROCE
13.88%
0.03%
EV
Common stock shares outstanding
36,658
29,958
29,466
Price
5.62
-29.22%
7.94
-19.55%
9.87
-17.54%
Market cap
206,018
-13.39%
237,867
-18.21%
290,829
-17.06%
EV
379,580
393,674
467,874
EBITDA
42,134
(10,458)
17,869
EV/EBITDA
9.01
26.18
Interest
18,090
18,184
17,261
Interest/NOPBT
54.37%
21,309.88%